Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Sep
25
Today In Oncology
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
Robert Kyle Myeloma Expert Dies at 98
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo